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Background: Despite the strong association between drug resistance and genetic mutations,
the value of molecular diagnosis of drug resistance to guide the treatment of multidrug-
resistant tuberculosis (MDR-TB) remains unclear. This is particularly relevant in
resource-limited areas, in which it is difficult to implement the drug susceptibility test.
Here, we focused on the association of drug susceptibility phenotype and genotype with
treatment outcomes in patients with MDR-TB.
Methods: In a prospective cohort study, we enrolled 252 consecutive patients with
confirmed MDR-TB between 2010 and 2013, and outcomes were followed-up over the
24-month treatment course in terms of clinical manifestation and sputum conversion.
All the isolates were tested for phenotypic susceptibility to second-line drugs in the
Mycobacteria Growth Indicator Tube based system, and genotypic mutations were assessed
by DNA sequencing.
Results: Among the 252 MDR-TB isolates, 88 (34.9%) were resistant to fluoroquinolones and/
or second-line injectable drugs, of which 65 (73.9%) harbored a mutation in drug resistance-
related genes (gyrA, rrs and eis). In addition, 85 individuals (33.7%) were also resistant to
pyrazinamide, with 87.1% containing the pncA mutation. Of 252 MDR-TB patients, 207
(82.1%) had known outcomes and 45 (17.9%) were lost to follow-up. Among those with
known outcomes, treatment succeeded in 85.8% with plain MDR-TB, 69.7% with initial
resistance to either a fluoroquinolone or second-line injective drugs, 37.5% with initial
resistance to pyrazinamide, 29.3% with initial extensively drug resistance. In contrast,
among those with known outcomes, treatment success and culture conversion depends
on the susceptibility to drug especially for pyrazinamide and fluoroquinolones. In
multivariate analysis, pyrazinamide resistance and its related pncA gene mutation were
independently associated with a lower risk of culture conversion on at 8 weeks and treat-
ment success, while fluoroquinolone resistance was negatively correlated with treatmentHealth, Fudan University, 138 Yi Xue Yuan Rd., Shanghai 200032, China.
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with treatment outcome.
Conclusion: Drug susceptibility testing for pyrazinamide and fluoroquinolones together
with genetic information appears to provide a clinically useful indicator of the treatment
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